Citeline logo with a tagline underneath that reads a Norstella company.
Contact Us
Report
March 9, 2026

Scrip Asks… Inside 2026: The Forces, Decisions and Challenges Redefining Biopharma

Scrip gathered predictions from a record 300-plus pharma executives, biotech leaders, investors and industry experts on the trends set to shape 2026.

From M&A and global competition to pricing, R&D advances and operational transformation through AI, their insights are collected across our five-part Scrip Asks series.

Why Download
  • See where biopharma funding is really flowing in 2026
    Get a clear picture of how financing conditions are changing. Find out what’s coming back, what’s still constrained, and which assets investors are backing.
  • Benchmark your strategy against industry leaders and active deal‑makers
    Use our data‑driven analysis and league‑table insights to compare your financing, growth, and valuation projections against other biopharma and medtech.
  • Understand how financing connects to M&A, innovation, and long‑term growth
    Go beyond the headlines to see how capital allocation links to patent risk, deal‑making, and innovation strategies.

Citeline may contact you about relevant products, services, and content. To opt out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.

サイトラインより、関連する製品・サービス・コンテンツに関する情報をお届けする場合があります。配信停止や受信内容の管理をご希望の場合は、プリファレンスセンターをご利用ください。

ご提供いただいた情報は、当社のプライバシー通知に基づき適切に取り扱います。


Discover more

Explore related solutions

Scrip

In-depth analysis of the global biopharma industry, offering news that goes beyond the headlines.